Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 20

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Trichomonas vaginalis Nucleic Acid Amplification Testing at an Urban HIV Clinic

Muzny, Christina A., Burkholder, Greer A., Fry, Karen R., Austin, Erika L., Schwebke, Jane R. · 2016 · Sexually Transmitted Diseases

Abstract

Background: Trichomonas vaginalis is the most common nonviral sexually transmitted infection. T. vaginalis nucleic acid amplification testing (NAAT) recently became available at the University of Alabama at Birmingham human immunodeficiency virus (HIV) clinic. The objective of this study was to determine the uptake of T. vaginalis NAAT testing among clinic providers during the first year of test availability in addition to T. vaginalis prevalence and predictors based on NAAT results. Methods: This was a retrospective review of HIV+ women and men ages ≥16 years at the University of Alabama at Birmingham HIV Clinic, including those receiving a T. vaginalis NAAT on a genitourinary specimen. Results: Between August 2014 and August 2015, 3163 HIV+ patients were seen (768 women, 2395 men), of whom 861 (27.3%) received a T. vaginalis NAAT; 402 women (52.3%) and 459 men (19.2%). Among those with T. vaginalis NAAT results, 70 (17.4%) of 402 women and 12 (2.6%) of 459 men (9 men who have sex with women, 1 man who has sex with men, 2 unknown) tested positive. In adjusted analyses for women, age ≤40 years (odds ratio [OR], 2.93; 95% confidence interval [CI], 1.23–6.96), current cocaine use (OR, 4.86; 95% CI, 1.57–15.06), and CD4 < 200 cells/mm 3 (OR, 6.09; 95% CI, 1.68–22.11) were significantly associated with increased odds of a positive T. vaginalis NAAT. For those with a positive T. vaginalis NAAT, treatment was prescribed for 65 (92.9%) of 70 women and 10 (83.3%) of 12 men. Conclusions: Initial uptake of T. vaginalis NAAT testing was modest at this HIV clinic yet identified a high prevalence among women tested. Emphasis on the need for testing in HIV+ women is necessary.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/olq.0000000000000479

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 29

  1. 2007, Infection with Trichomonas vaginalis increases the risk of HIV-1 acquisition, J Infect Dis, 195, 698, 10.1086/511278 · DOI · Paper page
  2. 2006, The associations between pelvic inflammatory disease, Trichomonas vaginalis infection, and positive herpes simplex virus type 2 serology, Sex Transm Dis, 33, 747, 10.1097/01.olq.0000218869.52753.c7 · DOI · Paper page
  3. 2015, Sexually transmitted diseases treatment guidelines, 2015, MMWR Recomm Rep, 64, 1
  4. 1988, Diagnosis of trichomoniasis. Comparison of conventional wet-mount examination with cytologic studies, cultures, and monoclonal antibody staining of direct specimens, JAMA, 259, 1223, 10.1001/jama.1988.03720080057028 · DOI · Paper page
  5. 2011, Molecular testing for Trichomonas vaginalis in women: results from a prospective U.S. clinical trial, J Clin Microbiol, 49, 4106, 10.1128/JCM.01291-11 · DOI
  6. 2014, Detection of Trichomonas vaginalis DNA by use of self-obtained vaginal swabs with the BD ProbeTec Qx assay on the BD Viper system, J Clin Microbiol, 52, 885, 10.1128/JCM.02966-13 · DOI
  7. 2009, Comparison of APTIMA Trichomonas vaginalis transcription-mediated amplification to wet mount microscopy, culture, and polymerase chain reaction for diagnosis of trichomoniasis in men and women, Am J Obstet Gynecol, 200, 188.e1, 10.1016/j.ajog.2008.10.005 · DOI · Paper page
  8. 2014, Added benefit of nucleic acid amplification testing for the diagnosis of Trichomonas vaginalis among men and women attending a sexually transmitted diseases clinic, Clin Infect Dis, 59, 834, 10.1093/cid/ciu446 · DOI · Paper page
  9. 2010, Darunavir outcomes study: comparative effectiveness of virologic suppression, regimen durability, and discontinuation reasons for three-class experienced patients at 48 weeks, AIDS Res Hum Retroviruses, 26, 1279, 10.1089/aid.2010.0059 · DOI
  10. 2015, Short communication: viral suppression is associated with increased likelihood of colorectal cancer screening among persons living with HIV/AIDS, AIDS Res Hum Retroviruses, 31, 519, 10.1089/aid.2014.0256 · DOI
  11. 2005, Validation of the World Health Organization Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): report of results from the Australian site, Drug Alcohol Rev, 24, 217, 10.1080/09595230500170266 · DOI · Paper page
  12. 2013, Trichomonas vaginalis infection among women receiving gynaecological care at an Alabama HIV Clinic, Sex Transm Infect, 89, 514, 10.1136/sextrans-2012-050889 · doi:10.1136/sextrans-2012-050889
  13. 2016, Trichomonas vaginalis and Mycoplasma genitalium: age-specific prevalence and disease burden in men attending a sexually transmitted infections clinic in Amsterdam, the Netherlands, Sex Transm Infect, 92, 83, 10.1136/sextrans-2015-052118 · DOI · Paper page
  14. 2012, Prevalence of urethral Trichomonas vaginalis in black and white men who have sex with men, Sex Transm Dis, 39, 739, 10.1097/OLQ.0b013e318264248b · DOI · Paper page
  15. 1993, Natural history of urogenital trichomoniasis in men, J Urol, 149, 1455, 10.1016/S0022-5347(17)36414-5 · DOI · Paper page
  16. 2011, Re-evaluating the treatment of nongonococcal urethritis: emphasizing emerging pathogens—a randomized clinical trial, Clin Infect Dis, 52, 163, 10.1093/cid/ciq074 · DOI · Paper page
  17. 2000, Comparative prevalence of infection with Trichomonas vaginalis among men attending a sexually transmitted diseases clinic, Sex Transm Dis, 27, 236, 10.1097/00007435-200004000-00010 · DOI
  18. 1995, Prevalence of Trichomonas vaginalis in a male sexually transmitted disease clinic population by interview, wet mount microscopy, and the InPouch TV test, Genitourin Med, 71, 405
  19. 2012, Use of nucleic acid amplification testing for diagnosis of anorectal sexually transmitted infections, J Clin Microbiol, 50, 2005, 10.1128/JCM.00185-12 · DOI
  20. 2008, Prevalence of rectal Trichomonas vaginalis and Mycoplasma genitalium in male patients at the San Francisco STD clinic, 2005–2006, Sex Transm Dis, 35, 797, 10.1097/OLQ.0b013e318177ec39 · DOI
  21. 2008, Factors associated with the prevalence and incidence of Trichomonas vaginalis infection among African American women in New York city who use drugs, J Infect Dis, 197, 503, 10.1086/526497 · DOI
  22. 2008, HIV, the clustering of sexually transmitted infections, and sex risk among African American women who use drugs, Sex Transm Dis, 35, 696, 10.1097/OLQ.0b013e31816b1fb8 · DOI
  23. 2002, Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HIV)-positive women and among HIV-negative women at high risk for HIV infection, Clin Infect Dis, 34, 1406, 10.1086/340264 · DOI
  24. 1998, Risk factors for trichomoniasis among women with human immunodeficiency virus (HIV) infection at a public clinic in Los Angeles County, California: implications for HIV prevention, Am J Trop Med Hyg, 58, 495, 10.4269/ajtmh.1998.58.495 · DOI
  25. 2003, Trichomonas vaginalis among HIV-Infected women: are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity?, Sex Transm Dis, 30, 839, 10.1097/01.OLQ.0000086609.95617.8D · DOI
  26. 2007, The prevalence of Trichomonas vaginalis infection among reproductive-age women in the United States, 2001–2004, Clin Infect Dis, 45, 1319, 10.1086/522532 · DOI · Paper page
  27. 2012, Prevalence of Trichomonas vaginalis and coinfection with Chlamydia trachomatis and Neisseria gonorrhoeae in the United States as determined by the Aptima Trichomonas vaginalis nucleic acid amplification assay, J Clin Microbiol, 50, 2601, 10.1128/JCM.00748-12 · DOI · Paper page
  28. 2011, Trichomonas vaginalis infection in women who submit self-obtained vaginal samples after internet recruitment, Sex Transm Dis, 38, 828, 10.1097/OLQ.0b013e3182228911 · DOI
  29. 2001, Trichomonas vaginalis, HIV, and African-Americans, Emerg Infect Dis, 7, 927, 10.3201/eid0706.010603 · DOI · Paper page

Cited by

See all 20

Metadata

Authors
Muzny, C. A., Burkholder, G. A., Fry, K. R., Austin, E. L., & Schwebke, J. R.
Affiliations
From the *Division of Infectious Diseases, and †Department of Biostatistics, University of Alabama at Birmingham School of Public Health, Birmingham, AL
Venue
Sexually Transmitted Diseases
Published
2016-08
Volume
43
Issue
8
Pages
483-488
ISSN
  • 1537-4521
  • 0148-5717
Cited by
20
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Trichomonas vaginalis Nucleic Acid Amplification Testing at an Urban HIV Clinic. https://app.cochat.ai/papers/10.1097/olq.0000000000000479
The paper
Muzny, C. A., Burkholder, G. A., Fry, K. R., Austin, E. L., & Schwebke, J. R. (2016). Trichomonas vaginalis Nucleic Acid Amplification Testing at an Urban HIV Clinic. Sexually Transmitted Diseases. https://doi.org/10.1097/olq.0000000000000479

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.